After injury, rapid intervention at the early stages of uncontrolled bleeding will reduce the overall associated morbidity and mortality. The complexities of trauma impair the natural blood clotting process, making it difficult to control bleeding with currently employed haemostatic agents. To address this, a snake venom hydrogel was developed that rapidly and stably controls the bleeding. This proof of concept bleeding control agent overcomes the many shortfalls of currently employed products. This project is at the interface of biomaterials and biomedical research to develop this further and explore alternate delivery scaffolds. 

If you are a driven and enthusiastic student looking to make impact through innovative research, please apply. A background or knowledge of biomaterials, biochemistry, cell culture or previous experience working with animals is highly desirable.

Further details can be found here.

Applications close June 6 2022.

The project will be undertaken at the University of Queensland, Australia, one of the worlds top 50 Universities, at the Australian Institute of Bioengineering and Nanotechnology, within Professor Alan Rowan's group. There is an existing research team with the required infrastructure, providing the required support to accelerate progress with funding from the US Department of Defense.

As this work employs human blood there are UQ occupational health and safety requirements for vaccination.